What question did this study set out to answer?

This research aims to uncover the shared biological pathways linking cardiovascular disease and cancer in individuals with diabetes.

June 7, 2026

2267-P: Shared Proteomic Pathways Linking Cardiovascular Disease and Cancer in People with Diabetes: A UK Biobank Cohort Analysis

Key Points

This research aims to uncover the shared biological pathways linking cardiovascular disease and cancer in individuals with diabetes.
Analyzed plasma proteomics of 3,215 UK Biobank participants with diabetes classified by complications.
Compared protein expression adjusted for multiple testing (FDR) against no complications.
Identified upregulated and downregulated proteins indicative of hemodynamic stress, kidney injury, inflammation, and metabolic changes.
Upregulated proteins, including NT-proBNP and GDF15, indicated hemodynamic stress and inflammation.
Downregulated proteins, such as S100A4 and TCL1A, suggested loss of matrix integrity and metabolic resilience.
Effects were most significant in the group with both cardiovascular disease and cancer.

Abstract

Introduction and Objective: People with diabetes frequently develop cardiovascular (CV) disease and cancer, but the shared biological pathways are unclear. We compared their proteomic signatures. Methods: We analyzed 3,215 UK Biobank participants with diabetes and plasma proteomics, classified as no complications, cancer only, CV disease only, or both. Protein expression was FDR-adjusted versus no complications. Results: Upregulated proteins included NT-proBNP, HAVCR1, GDF15, and IGFBP2, reflecting hemodynamic stress, kidney injury, inflammation, and metabolic signaling. Downregulated proteins (S100A4, DCXR, SDC4, TCL1A) suggested reduced matrix integrity and metabolic resilience. Effects were strongest in the combined CV and cancer group. Conclusion: CV disease and cancer in diabetes share key proteomic pathways, supporting a systems-based multimorbidity model. Disclosure J. Calvo-Marin: Speaker's Bureau; Current; Novo Nordisk, AstraZeneca, Abbott Diabetes, Roche Diabetes Care. F. Ruiz Salazar: Speaker's Bureau; Current; Abbott Diagnostics, AstraZeneca, Novo Nordisk A/S. Advisory Panel; Current; Roche Diagnostics. V. Mora-Gomez: None. M. Lutz: None. G. Torrealba-Acosta: None.

Demander à l'IA

Bookmark